Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data
MT-601 demonstrated robust safety profile with no dose limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS) in the dose escalation cohort
“We are excited to highlight the promising findings from our Phase 1 APOLLO study at the ASH Meeting,” said
The Phase 1 APOLLO study (clinicaltrials.gov identifier: NCT05798897) is a multicenter, open-label trial investigating MT-601, a Multi-Antigen Recognizing (MAR)-T cell therapy, in patients with B cell lymphomas. Among patients with Non-Hodgkin lymphoma (NHL), including those who relapsed after anti-CD19 directed CAR-T cell therapy, the objective response rate (ORR) was 66% (8 out of 12) with 50% achieving a complete response (CR). Responses were durable, ranging from 3 to 24 months, with five patients remaining in remission for 6 months or longer, including three patients with responses exceeding 12 months. In Hodgkin lymphoma (HL), the ORR was 78% (7 out of 9), with 11% achieving a CR. MT-601 was well tolerated by all study participants, with no reported dose limiting toxicities or ICANS. Only two participants experienced Grade 1 cytokine release syndrome (CRS) (fever; no treatment was required).
“We are encouraged by the robust safety profile and the potential clinical benefit we continue to observe across multiple histologies, highlighting the versatility of MT-601,” commented
Poster Presentation Details:
Safety and Efficacy of MT-601 in Relapsed or Refractory (r/r) Hodgkin Lymphoma
Presenting Author:
Publication Number: 1846
Session
Session Date & Time:
Room: OCCC – West Halls B3-B4
MT-601 Demonstrates Favorable Safety and Durable Responses in Relapsed or Refractory (r/r) Non-Hodgkin Lymphoma (NHL)
Presenting Author:
Publication Number: 5944
Session
Session Date & Time:
Room: OCCC – West Halls B3-B4
About MT-601
The Company’s lead product, MT-601, is a multi-antigen recognizing (MAR) T cell product that utilizes a non-genetically modified approach that specifically targets six different tumor antigens upregulated in lymphoma cells (Survivin, PRAME, WT-1, NY-ESO-1, SSX-2, MAGEA-4). Marker is currently investigating MT-601 in the Company-sponsored Phase 1 APOLLO trial (clinicaltrials.gov identifier: NCT05798897) for the treatment of patients with lymphoma who have relapsed after or are not candidates for anti-CD19 CAR-T cell therapies.
About APOLLO
The APOLLO trial (clinicaltrials.gov Identifier: NCT05798897) is a Phase 1, multicenter, open-label study designed to evaluate the safety and efficacy of MT-601 in participants with relapsed or refractory lymphoma who have either failed anti-CD19 chimeric antigen receptor (CAR) T cell therapy or are not candidates for anti-CD19 CAR-T cell therapy. The primary objective of this exploratory Phase 1 clinical trial is to evaluate the optimum dose, safety, and preliminary efficacy of MT-601 in participants with various lymphoma subtypes. The APOLLO study is supported by the
About MAR-T cells
The multi-antigen recognizing (MAR) T cell platform (formerly known as multiTAA-specific T cells) is a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient's/donor’s blood capable of recognizing a broad range of tumor antigens. Unlike other T cell therapies, MAR-T cells allow the recognition of hundreds of different epitopes within up to six tumor-specific antigens, thereby reducing the possibility of tumor escape. Since MAR-T cells are not genetically engineered, Marker believes that its product candidates will be easier and less expensive to manufacture, with an improved safety profile compared to current engineered T cell approaches and may provide patients with meaningful clinical benefits.
About
To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.
Forward-Looking Statements
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and the timing, conduct, interim results announcements and outcomes of our clinical trials of our product candidates, including MT-601 for the treatment of patients with lymphoma. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at WWW.SEC.GOV. The Company assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release except as may be required by law.
Media and Investor Contact
+1 (713) 400-6400
investor.relations@markertherapeutics.com
Source: Marker Therapeutics